SCHEMBL953949

SCHEMBL953949

Cc1nn2ccccc2c1-c1nc(-c2ccccc2C(F)(F)F)c(C(=O)O)s1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.43
DBF4 Q9UBU7 2/20 0.43
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
RORC P51449 7/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
F2RL3 Q96RI0 1/20 0.36
KMO O15229 1/20 0.35
EPHB3 P54753 1/20 0.34
PTPN1 P18031 1/20 0.34
PLK1 P53350 1/20 0.34
NTRK1 P04629 1/20 0.34
SPR P35270 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL952856 0.91 CDC7 (0.54) CDC7DBF4CCNE1CDK2PPARD
SCHEMBL955904 0.88 CDC7 (0.40) CDC7DBF4ALDH1A1HPGDSMN1; SMN2
SCHEMBL954275 0.88 CDC7 (0.46) CDC7DBF4CCNE1CDK2ALDH1A1
SCHEMBL953589 0.86 CDC7 (0.43) CDC7DBF4PPARDPPARAALDH1A1
SCHEMBL958443 0.85 CDC7 (0.36) CDC7DBF4ALDH1A1RORCSMN1; SMN2
SCHEMBL953113 0.84 CDC7 (0.50) CDC7DBF4CCNE1CDK2ALDH1A1
SCHEMBL951780 0.84 HIF1A (0.39) ALDH1A1HPGDSMN1; SMN2
SCHEMBL953870 0.82 SMN1; SMN2 (0.39) CDC7DBF4ALDH1A1HPGDRORC
SCHEMBL952871 0.82 F2RL3 (0.38) SMN1; SMN2F2RL3
SCHEMBL956090 0.82 PTGS1 (0.36) CDC7DBF4RORCSMN1; SMN2F2RL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 CDC7 601/4885DBF4 3288/4885CCNE1 1329/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 CDC7 1063/4885DBF4 3779/4885CCNE1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.